Endpoints News
Endpoints News delivers timely and in-depth coverage of the biotechnology and pharmaceutical industries, focusing on drug development, regulatory affairs, and market trends.
Latest News
- Updated: FDA asks for data on Lilly’s Foundayo to assess heart, liver risks
- Replimune looks ahead as repeat CRL speeds the company's decline
- Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
- Endpoints biopharma sentiment survey for Q2 2026
- Harbinger raises $100M; Astellas to close Seattle site
- J&J increasingly confident it can manage Stelara cliff, but work remains
- Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio